An upcoming catalyst is a near‑term event that could move an asset’s value or outlook. Think clinical readouts, trial starts/completions, regulatory filings or decisions, etc. These are discrete milestones tied to development progress.
It’s not the same as anticipated launch year. Launch year is a later, outcome-based milestone tied to approval and commercialization, which sits within broader timeline/approval projections.
So catalysts = interim events along the way. Launch year = end goal if things go well.
Does that match how you’re seeing it in the platform, or is there a specific asset field that’s confusing you?